Anúncio
Anúncio

VTGN

VTGN logo

Vistagen Therapeutics, Inc. Common Stock

0.74
USD
Patrocinado
+0.02
+2.55%
07 de jan., 16:00 UTC -5
Encerrado
exchange

Pós-Mercado

0.74

0.00
+0.27%

Relatórios de Lucros VTGN

Rácio de surpresa positiva

VTGN separação 19 de 37 últimas estimativas.

51%

Próximo Relatório

Data do Próximo Relatório
11 de fev. de 2026
Estimate for Q3 26 (Revenue/ EPS)
$373.32K
/
-$0.48
Mudanças implicadas de Q2 26 (Revenue/ EPS)
+44.70%
/
-11.11%
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+59.54%
/
+4.35%

Vistagen Therapeutics, Inc. Common Stock earnings per share and revenue

On 13 de nov. de 2025, VTGN reported earnings of -0.54 USD per share (EPS) for Q2 26, missing the estimate of -0.48 USD, resulting in a -11.23% surprise. Revenue reached 258.00 mil, compared to an expected 248.20 mil, with a 3.95% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analistas forecast an EPS of -0.48 USD, with revenue projected to reach 373.32 mil USD, implying an diminuir of -11.11% EPS, and aumentar of 44.70% in Revenue from the last quarter.
FAQ
For Q2 2026, Vistagen Therapeutics, Inc. Common Stock reported EPS of -$0.54, missing estimates by -11.23%, and revenue of $258.00K, 3.95% above expectations.
The stock price moved -- 0%, changed from $3.80 before the earnings release to $3.80 the day after.
The next earning report is scheduled for 11 de fev. de 2026.
Based on 7 analistas, Vistagen Therapeutics, Inc. Common Stock is expected to report EPS of -$0.48 and revenue of $373.32K for Q3 2026.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio